SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-06-18
👔
BridgeBio Oncology Therapeutics, Inc.
@BBOT_InsiderForm 4 Filing: Kumar Neil Acquires (Grant) shares of $BBOT
STOCK AWARD / GRANT
⚡ MATERIALITY: 1/10
corporate issuer
BridgeBio Oncology Therapeutics, Inc.
Ticker: $BBOT
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-06-16
Shares: 31,675
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Kumar Neil, holds the title of Director at BridgeBio Oncology Therapeutics, Inc..
On 2026-06-16, the insider transacted 31,675 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Kumar Neil (Director) was granted $0 of $BBOT
Post-Transaction Position: 31,675 shares
SEC Accession No: 0001193125-26-276033 (CIK: 1742485)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.